(Q33741025)

English

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome (English)

1 reference

Europe PubMed Central

29 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

17

0 references

Jean-Valère Malfuson

13

object named as

Jean-Valère Malfuson

0 references

Jean-Pierre Marolleau

7

object named as

Jean-Pierre Marolleau

0 references

Christine Chomienne

object named as

Christine Chomienne

18

0 references

16

object named as

Pierre Fenaux

1 reference

Europe PubMed Central

29 July 2017

20

object named as

Hervé Dombret

1 reference

Europe PubMed Central

29 July 2017

Pierre-Yves Boëlle

4

object named as

Pierre-Yves Boëlle

1 reference

Europe PubMed Central

29 July 2017

6

object named as

Pascal Turlure

1 reference

Europe PubMed Central

29 July 2017

Philippe Rousselot

12

object named as

Philippe Rousselot

1 reference

Europe PubMed Central

29 July 2017

Emmanuel Raffoux

1

object named as

Emmanuel Raffoux

1 reference

Europe PubMed Central

29 July 2017

Christian Récher

3

object named as

Christian Recher

1 reference

Europe PubMed Central

29 July 2017

8

object named as

Oumedaly Reman

1 reference

Europe PubMed Central

29 July 2017

Marie-Thérèse Daniel

15

object named as

Marie-Thérèse Daniel

1 reference

Europe PubMed Central

29 July 2017

19

object named as

Sylvie Chevret

1 reference

Europe PubMed Central

29 July 2017

author name string

Audrey Cras

2

1 reference

Europe PubMed Central

29 July 2017

Adrienne de Labarthe

5

1 reference

Europe PubMed Central

29 July 2017

Jean-Pierre Marolleau

7

1 reference

Europe PubMed Central

29 July 2017

Claude Gardin

9

1 reference

Europe PubMed Central

29 July 2017

Maud Victor

10

1 reference

Europe PubMed Central

29 July 2017

Sébastien Maury

11

1 reference

Europe PubMed Central

29 July 2017

Odile Maarek

14

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

1 May 2010

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

1

1 reference

Europe PubMed Central

29 July 2017

1

1 reference

Europe PubMed Central

29 July 2017

34-42

1 reference

Europe PubMed Central

29 July 2017

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

Gene silencing in cancer in association with promoter hypermethylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

14 July 2018

Treatment of acute myelogenous leukemia with outpatient azacitidine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

30 October 2018

Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

30 October 2018

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4053545

30 October 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21293051

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/21293051

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33741025&oldid=1939968698"